Are Peptides FDA Approved?

The question is asked constantly and cannot be answered as asked, because FDA does not approve categories of molecule. It approves a specific product, made by a specific manufacturer, for a specific indication, in a specific population, at specific doses.

Asking whether peptides are FDA approved is like asking whether small molecules are FDA approved. Aspirin is; most organic compounds are not.

Peptides that are approved

A number of peptide drugs hold FDA approval. Among those covered on this site:

• Semaglutide — approved across several products for type 2 diabetes, chronic weight management, cardiovascular risk reduction in a defined population, and noncirrhotic MASH with moderate to advanced fibrosis.
• Tirzepatide — approved for type 2 diabetes, for chronic weight management, and for moderate to severe obstructive sleep apnoea in adults with obesity.
• Tesamorelin — approved for the reduction of excess abdominal fat in adults with HIV and lipodystrophy ^[2].

Beyond this site's current library, insulin analogs, leuprolide, octreotide, teriparatide, liraglutide and many others are approved peptide drugs. Peptide pharmacology is mainstream medicine.

What approval actually means

Approval is a judgment that, for a defined use in a defined population, the demonstrated benefit outweighs the demonstrated risk, on the basis of evidence the agency has reviewed.

Three things follow that are routinely missed:

It is indication-specific. Tesamorelin's label states explicitly that it is not indicated for weight loss management. A drug approved to reduce visceral fat in one population is not thereby a weight-loss drug ^[2].

It is not a safety certificate. Both semaglutide and tirzepatide carry boxed warnings — the most serious warning FDA applies — for thyroid C-cell tumour findings in rodents. Approved does not mean risk-free; it means the risks are known, labelled and judged acceptable for the approved use.

It attaches to the product, not the molecule. Compounded versions of an approved peptide are not the approved product. They have not been reviewed for safety, efficacy or manufacturing quality.

Peptides that are not approved

Most compounds sold and discussed as "research peptides" hold no approval of any kind. BPC-157, TB-500, CJC-1295, ipamorelin, GHK-Cu and MOTS-c are all in this group.

Several also appear on FDA's list of bulk drug substances relevant to compounding under section 503A. As of the April 2026 update to that page, ipamorelin acetate sits in Category 2 — substances for which the agency has identified significant safety risks — while BPC-157, CJC-1295, GHK-Cu, MOTS-c and thymosin beta-4 fragment (TB-500) appear among substances whose nominations were withdrawn ^[1].

Neither listing is an approval. Both mean the compound cannot be lawfully compounded from bulk substance under 503A.

A four-question test

Given any peptide product, these four questions settle its status:

1. Is there an approved product containing this active ingredient? Search Drugs@FDA. If nothing comes back, there is no approval.
2. What is the approved indication? Read the label's INDICATIONS AND USAGE section, and then read LIMITATIONS OF USE — that is where the agency says what the drug is not for.
3. Is this specific product the approved one? A compounded or grey-market version of an approved molecule is not the approved product.
4. What evidence exists for the use being claimed? Approval for one indication is not evidence for another.

Why this distinction is worth the effort

The peptide market runs on category confusion. "Peptides are FDA approved" is technically true of some peptides and used to sell others. Keeping approval attached to products and indications, rather than to a class of molecule, dissolves most of the marketing in this space on contact.

Every compound profile on Peptide Insider states its approval status in the Insider Summary near the top of the page, and again in a dedicated regulatory section, for exactly this reason.